Catheter ablation versus medical therapy for atrial fibrillation with prior stroke history: a prospective propensity score-matched cohort study.
- Author:
Wen-Li DAI
1
;
Zi-Xu ZHAO
1
;
Chao JIANG
1
;
Liu HE
1
;
Ke-Xin YAO
1
;
Yu-Feng WANG
1
;
Ming-Yang GAO
1
;
Yi-Wei LAI
1
;
Jing-Rui ZHANG
1
;
Ming-Xiao LI
1
;
Song ZUO
1
;
Xue-Yuan GUO
1
;
Ri-Bo TANG
1
;
Song-Nan LI
1
;
Chen-Xi JIANG
1
;
Nian LIU
1
;
De-Yong LONG
1
;
Xin DU
1
;
Cai-Hua SANG
1
;
Jian-Zeng DONG
1
;
Chang-Sheng MA
1
Author Information
- Publication Type:Journal Article
- From: Journal of Geriatric Cardiology 2023;20(10):707-715
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Patients with atrial fibrillation (AF) and prior stroke history have a high risk of cardiovascular events despite anticoagulation therapy. It is unclear whether catheter ablation (CA) has further benefits in these patients.
METHODS:AF patients with a previous history of stroke or systemic embolism (SE) from the prospective Chinese Atrial Fibrillation Registry study between August 2011 and December 2020 were included in the analysis. Patients were matched in a 1:1 ratio to CA or medical treatment (MT) based on propensity score. The primary outcome was a composite of all-cause death or ischemic stroke (IS)/SE.
RESULTS:During a total of 4.1 ± 2.3 years of follow-up, the primary outcome occurred in 111 patients in the CA group (3.3 per 100 person-years) and in 229 patients in the MT group (5.7 per 100 person-years). The CA group had a lower risk of the primary outcome compared to the MT group [hazard ratio (HR) = 0.59, 95% CI: 0.47-0.74, P < 0.001]. There was a significant decreasing risk of all-cause mortality (HR = 0.43, 95% CI: 0.31-0.61, P < 0.001), IS/SE (HR = 0.73, 95% CI: 0.54-0.97, P = 0.033), cardiovascular mortality (HR = 0.32, 95% CI: 0.19-0.54, P < 0.001) and AF recurrence (HR = 0.33, 95% CI: 0.30-0.37, P < 0.001) in the CA group compared to that in the MT group. Sensitivity analysis generated consistent results when adjusting for time-dependent usage of anticoagulants.
CONCLUSIONS:In AF patients with a prior stroke history, CA was associated with a lower combined risk of all-cause death or IS/SE. Further clinical trials are warranted to confirm the benefits of CA in these patients.
